Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NovAnI

Financiado

Indentification and optimisation of novel anti infective agents using multiple h...

Indentification and optimisation of novel anti infective agents using multiple hit identification strategies Given the rapid emergence of anti-infective resistance, drugs with a novel mode of action are urgently needed. Because of an exhaustion of existing strategies, a low return on investment and the fact that anti-infectives are diffi... ver más

31/01/2023

HZI

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

HELMHOLTZZENTRUM FUR INFEKTIONSFORSCHUNG GMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-01-31

ERC-2017-STG: ERC Starting Grant

I+D

Cerrada hace 8 años

0% 100% 100%

2 Participantes

HZI

1.50M€ | Lider

PEPIÑO

118.95K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PDC2021-121544-I00 DISEÑO DE UNA NUEVA CLASE DE ANTIMICROBIANOS CONTRA INFECCIO... 133K€ Cerrado

BFU2014-59389-P BIOLOGIA ESTRUCTURAL DE PROCESOS CRITICOS DE REMODELADO DE L... 399K€ Cerrado

SAF2010-15076 ANTIBIOTICOS INHIBIDORES DE NOVEDOSAS DIANAS TERAPEUTICAS: D... 204K€ Cerrado

PCI2019-103488 DESARROLLO DE NUEVOS INHIBIDORES DE LA TOLERANCIA MICOBACTER... 140K€ Cerrado

ChronosAntibiotics Exploring the bacterial cell cycle to re sensitize antibioti... 3M€ Cerrado

AnLeadOp Antibiotic Lead Optimization 150K€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2018-01-12
Fecha Fin: 2023-01-31

Líder del proyecto

HELMHOLTZZENTRUM FUR INFEKTIONSFORSCHUNG GMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Descripción del proyecto Given the rapid emergence of anti-infective resistance, drugs with a novel mode of action are urgently needed. Because of an exhaustion of existing strategies, a low return on investment and the fact that anti-infectives are difficult to develop (e.g., crossing the peculiar cell wall of Mycobacterium tuberculosis), promising un(der)explored targets and unconventional hit-identification strategies are needed. I have selected three anti-infective targets based on their biochemical context for which few or no small-molecule inhibitors are known: 1) The antimalarial and antituberculotic drug target DXS is part of a unique biosynthetic pathway for pathogens that is absent in humans, thereby circumventing selectivity issues. Both diseases are a serious health threat with around 1.9 million deaths per year. 2) Energy-coupling factor transporters are essential vitamin importers for pathogens such as Staphylococcus aureus, the causative agent of methicillin-resistant Staphylococcus aureus (MRSA) infections. 3) The DNA polymerase sliding clamp DnaN has polymerase and DNA repair activities and is an excellent drug target for the development of antibacterial agents against Gram-negative and –positive bacteria given the low incidence of resistance development. I will address these targets, employing a unique combination of potentially synergistic hit-identification strategies that take into account protein flexibility, provide access to novel scaffolds and give me a cutting edge for the development of novel anti-infectives. This ERC proposal builds on my experience with the first two targets and provides an excellent platform for the new target DnaN. My expertise in synthetic organic and medicinal chemistry and established hit-identification strategies together with my collaborations with protein crystallographers, biochemists and pharmacologists place me in an excellent position for not only achieving the goals of this interdisciplinary proposal but also going beyond it.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores